Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Lenvatinib in advanced intrahepatic cholangiocarcinoma
NCT05342194Phase 3Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jun 2023
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jun 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05342194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05342194.